Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Susan Branford, PhD FFSc (RCPA), Carol Wadham, PhD, Naranie Shanmuganathan, MBBS FRACP FRCPA, Daniel Thomson, PhD BSc, NUR Hezrin Shahrin, PhD, Jinghua Feng, PhD, Verity A Saunders, Wendy T Parker, PhD, Rob King, Paul Wang, PhD, Hamish S Scott, PhD FFSc (RCPA), Andreas Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 2918.

https://doi.org/10.1182/blood-2019-123242

Published: 2019

Journal Articles

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Blood (2019) 134 (Supplement_1): 1704.

https://doi.org/10.1182/blood-2019-126462

Published: 2019

Journal Articles

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Justine E Marum, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Martin C. Mueller, Christian T. Dietz, PhD, Ieuan Walker, MSc, BSc, MBBS, Nathalie Nataren, BSc, Zoe Donaldson, BSc, Wendy T Parker, PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Andreas W Schreiber, PhD, Susan Branford, PhD FFSc (RCPA)

Blood (2016) 128 (22): 1219.

https://doi.org/10.1182/blood.V128.22.1219.1219

Published: 2016

Journal Articles

The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different

Blood (2016) 128 (22): 3157.

https://doi.org/10.1182/blood.V128.22.3157.3157

Published: 2016

Journal Articles

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Blood (2015) 126 (23): 1644.

https://doi.org/10.1182/blood.V126.23.1644.1644

Published: 2015

Journal Articles

Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib

Debora A Casolari, PhD, Diana G Iarossi, BSc (Hons), Carolyn M Butcher, MMedSc(Hons), Sarah C Bray, PhD, Wendy T Parker, PhD, Chris N Hahn, PhD, Susan Branford, PhD, Peter Bardy, MD, Ian D Lewis, MBBS, PhD, Hamish S Scott, PhD, Steven W Lane, MD PhD, David M Ross, MBBS, PhD FRACP, FRCPA, Richard J D'Andrea, PhD

Blood (2014) 124 (21): 1882.

https://doi.org/10.1182/blood.V124.21.1882.1882

Published: 2014

Journal Articles

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Susan Branford, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Wendy T Parker, PhD, Jodi Braley, John F Seymour, MBBS, FRACP, PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 816.

https://doi.org/10.1182/blood.V124.21.816.816

Published: 2014

Journal Articles

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

Wendy T Parker, PhD, Stuart R Phillis, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, David Lawrence, BCS, Andreas Schreiber, PhD, Paul Wang, PhD, Joel Geoghegan, MSc, Stephanie Lustgarten, PhD, Graeme Hodgson, Victor M. Rivera, PhD, Timothy P. Hughes, MD, Hamish Scott, PhD, Susan Branford, PhD

Blood (2014) 124 (21): 399.

https://doi.org/10.1182/blood.V124.21.399.399

Published: 2014

Journal Articles

PCR-Mediated Recombination Can Lead To Artificial Chimera Formation, Which May Pose As BCR-ABL1 Compound Mutations

Wendy T Parker, PhD, Stuart R Phillis, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, Hamish S Scott, PhD, Susan Branford, PhD

Blood (2013) 122 (21): 4014.

https://doi.org/10.1182/blood.V122.21.4014.4014

Published: 2013

Journal Articles

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Haley Altamura, BSc, Nicola Roberts, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Bronte A Jamison, BSc, Chani Field, BSc, Stephanie Lustgarten, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD

Blood (2013) 122 (21): 651.

https://doi.org/10.1182/blood.V122.21.651.651

Published: 2013

Journal Articles

Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months

Susan Branford, PhD, Nicola Roberts, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Haley Altamura, BSc, Wendy T Parker, PhD, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 254.

https://doi.org/10.1182/blood.V122.21.254.254

Published: 2013

Journal Articles

The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Bronte A Jamison, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Hamish S Scott, PhD, Timothy P Hughes, MD, Susan Branford, PhD

Blood (2012) 120 (21): 1692.

https://doi.org/10.1182/blood.V120.21.1692.1692

Published: 2012

Journal Articles

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy

Catherine C Smith, MD, Michael Brown, PhD, Wendy T Parker, PhD, Kimberly Lin, BS, Kevin Travers, PhD, Susana Wang, Susan Branford, PhD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 917.

https://doi.org/10.1182/blood.V120.21.917.917

Published: 2012

Journal Articles

Multiple Low Level Mutations Identifies Imatinib Resistant CML Patients At Risk of Poor Response to Second-Line Inhibitor Therapy, Irrespective of the Resistance Profile of the Mutations

Wendy T Parker, PhD, Musei Ho, Hamish S Scott, PhD, Timothy P. Hughes, MD, Susan Branford, PhD

Blood (2011) 118 (21): 111.

https://doi.org/10.1182/blood.V118.21.111.111

Published: 2011

Journal Articles

Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance

Wendy T Parker, PhD, Musei Ho, Rebecca M Lawrence, Darryl L Irwin, PhD, Hamish S Scott, PhD, Timothy Hughes, MD, MBBS, Susan Branford, PhD

Blood (2010) 116 (21): 891.

https://doi.org/10.1182/blood.V116.21.891.891

Published: 2010

Journal Articles

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

Carine Tang, BSc., (Hons), Lisa Schafranek, BSc., (Hons), Dale Watkins, BSc., (Hons), Wendy T Parker, PhD, Jodi Prime, BSc., Deborah L White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 3383.

https://doi.org/10.1182/blood.V116.21.3383.3383

Published: 2010

NARROW

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

PCR-Mediated Recombination Can Lead To Artificial Chimera Formation, Which May Pose As BCR-ABL1 Compound Mutations

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months

The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy

Multiple Low Level Mutations Identifies Imatinib Resistant CML Patients At Risk of Poor Response to Second-Line Inhibitor Therapy, Irrespective of the Resistance Profile of the Mutations

Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only